{
  "symbol": "NOW",
  "year": 2025,
  "Period": "Q2",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.2791,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.099
  },
  "top_positive": [
    {
      "sent": "As of March 31, 2025, we had 207 million shares of common stock, net of treasury stock, outstanding and had reserved shares of common stock for future issuance as follows (in thousands): March 31, 2025 Stock plans: Options outstanding 946 RSUs (1) 6,825 Shares of common stock available for future grants: Amended and Restated 2021 Equity Incentive Plan (2) 7,624 Amended and Restated 2012 Employee Stock Purchase Plan (2) 7,898 Total shares of common stock reserved for future issuance 23,293 (1) Represents the number of shares issuable upon settlement of outstanding restricted stock units (\u201cRSUs\u201d) and performance-based RSUs (\u201cPRSUs\u201d), as discussed in Note 13.",
      "score": 0.9747
    },
    {
      "sent": "As of March 31, 2025, we had 207 million shares of common stock, net of treasury stock, outstanding and had reserved shares of common stock for future issuance as follows (in thousands): March 31, 2025 Stock plans: Options outstanding 946 RSUs (1) 6,825 Shares of common stock available for future grants: Amended and Restated 2021 Equity Incentive Plan (2) 7,624 Amended and Restated 2012 Employee Stock Purchase Plan (2) 7,898 Total shares of common stock reserved for future issuance 23,293 (1) Represents the number of shares issuable upon settlement of outstanding restricted stock units (\u201cRSUs\u201d) and performance-based RSUs (\u201cPRSUs\u201d), as discussed in Note 13.",
      "score": 0.9747
    },
    {
      "sent": "As of March 31, 2025, we had 207 million shares of common stock, net of treasury stock, outstanding and had reserved shares of common stock for future issuance as follows (in thousands): March 31, 2025 Stock plans: Options outstanding 946 RSUs (1) 6,825 Shares of common stock available for future grants: Amended and Restated 2021 Equity Incentive Plan (2) 7,624 Amended and Restated 2012 Employee Stock Purchase Plan (2) 7,898 Total shares of common stock reserved for future issuance 23,293 (1) Represents the number of shares issuable upon settlement of outstanding restricted stock units (\u201cRSUs\u201d) and performance-based RSUs (\u201cPRSUs\u201d), as discussed in Note 13.",
      "score": 0.9747
    }
  ],
  "top_negative": [
    {
      "sent": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in millions) (unaudited) Three Months Ended March 31, 2025 2024 Cash flows from operating activities: Net income $ 460 $ 347 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 160 130 Amortization of deferred commissions 145 131 Stock-based compensation 470 422 Deferred income taxes 32 28 Other 4 ( 18 ) Changes in operating assets and liabilities, net of effect of business combinations: Accounts receivable 901 715 Deferred commissions ( 155 ) ( 165 ) Prepaid expenses and other assets ( 139 ) ( 106 ) Accounts payable 234 107 Deferred revenue ( 148 ) ( 10 ) Accrued expenses and other liabilities ( 287 ) ( 240 ) Net cash provided by operating activities $ 1,677 $ 1,341 Cash flows from investing activities: Purchases of property and equipment ( 205 ) ( 135 ) Business combinations, net of cash acquired ( 18 ) ( 10 ) Purchases of other intangibles ( 34 ) ( 21 ) Purchases of investments ( 1,140 ) ( 1,605 ) Purchases of non-marketable investments ( 4 ) ( 42 ) Sales and maturities of investments 1,181 1,073 Other 3 6 Net cash used in investing activities $ ( 217 ) $ ( 734 ) Cash flows from financing activities: Proceeds from employee stock plans 153 131 Repurchases of common stock ( 298 ) ( 175 ) Taxes paid related to net share settlement of equity awards ( 253 ) ( 215 ) Business combination \u2014 ( 184 ) Net cash used in financing activities $ ( 398 ) $ ( 443 ) Foreign currency effect on cash, cash equivalents and restricted cash 5 ( 4 ) Net change in cash, cash equivalents and restricted cash 1,067 160 Cash, cash equivalents and restricted cash at beginning of period 2,310 1,904 Cash, cash equivalents and restricted cash at end of period $ 3,377 $ 2,064 Cash, cash equivalents and restricted cash at end of period: Cash and cash equivalents $ 3,369 $ 2,056 Restricted cash included in prepaid expenses and other current assets 8 8 Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows $ 3,377 $ 2,064 Supplemental disclosures of other cash flow information: Interest paid $ 11 $ 11 Income tax\nlows (in millions): March 31, 2025 Due within 1 year $ 3,228 Due in 1 year through 5 years 4,248 Instruments not due in single maturity 87 Total $ 7,563 As of March 31, 2025 and December\u00a031, 2024, unrealized losses of $ 16 million and $ 18 million, respectively, are from available-for-sale debt securities in a continuous unrealized loss position greater than 12 months.",
      "score": -0.8176
    },
    {
      "sent": "We accrue for loss contingencies when it is both probable that we will incur the loss and when we can reasonably estimate the amount of the loss or range of loss.",
      "score": -0.802
    },
    {
      "sent": "QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISK There have been no material changes in our market risk compared to the disclosures in Part II, Item 7A in our Annual Report on Form 10-K for the year ended December\u00a031, 2024, which was filed with the SEC on January\u00a030, 2025.",
      "score": -0.7297
    }
  ],
  "forward_snippets": [
    "For all available-for-sale debt securities that were in unrealized loss positions, we have determined that it is more likely than not we will hold the securities until maturity or a recovery of the cost basis.",
    "RPO excludes contracts that are billed in arrears, such as certain time and materials contracts, as we apply the \u201cright to invoice\u201d practical expedient under relevant accounting guidance.",
    "As of March 31, 2025, the total non-cancellable RPO under our contracts with customers was $ 22.1 billion and we expect to recognize revenues on approximately 47 % of these RPO over the following 12 months.",
    "RPO excludes contracts that are billed in arrears, such as certain time and materials contracts, as we apply the \u201cright to invoice\u201d practical expedient under relevant accounting guidance.",
    "As of March 31, 2025, the total non-cancellable RPO under our contracts with customers was $ 22.1 billion and we expect to recognize revenues on approximately 47 % of these RPO over the following 12 months."
  ],
  "curated_text": "Symbol: NOW. Year: 2025. Period: Q2. ReportType: Q10. Section: Management Discussion and Analysis (MD&A). Key metrics include sentiment, forward outlook, and risk hedging.  Top positive sentences: As of March 31, 2025, we had 207 million shares of common stock, net of treasury stock, outstanding and had reserved shares of common stock for future issuance as follows (in thousands): March 31, 2025 Stock plans: Options outstanding 946 RSUs (1) 6,825 Shares of common stock available for future grants: Amended and Restated 2021 Equity Incentive Plan (2) 7,624 Amended and Restated 2012 Employee Stock Purchase Plan (2) 7,898 Total shares of common stock reserved for future issuance 23,293 (1) Represents the number of shares issuable upon settlement of outstanding restricted stock units (\u201cRSUs\u201d) and performance-based RSUs (\u201cPRSUs\u201d), as discussed in Note 13. As of March 31, 2025, we had 207 million shares of common stock, net of treasury stock, outstanding and had reserved shares of common stock for future issuance as follows (in thousands): March 31, 2025 Stock plans: Options outstanding 946 RSUs (1) 6,825 Shares of common stock available for future grants: Amended and Restated 2021 Equity Incentive Plan (2) 7,624 Amended and Restated 2012 Employee Stock Purchase Plan (2) 7,898 Total shares of common stock reserved for future issuance 23,293 (1) Represents the number of shares issuable upon settlement of outstanding restricted stock units (\u201cRSUs\u201d) and performance-based RSUs (\u201cPRSUs\u201d), as discussed in Note 13. As of March 31, 2025, we had 207 million shares of common stock, net of treasury stock, outstanding and had reserved shares of common stock for future issuance as follows (in thousands): March 31, 2025 Stock plans: Options outstanding 946 RSUs (1) 6,825 Shares of common stock available for future grants: Amended and Restated 2021 Equity Incentive Plan (2) 7,624 Amended and Restated 2012 Employee Stock Purchase Plan (2) 7,898 Total shares of common stock reserved for future issuance 23,293 (1) Represents the number of shares issuable upon settlement of outstanding restricted stock units (\u201cRSUs\u201d) and performance-based RSUs (\u201cPRSUs\u201d), as discussed in Note 13. Top negative sentences: CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in millions) (unaudited) Three Months Ended March 31, 2025 2024 Cash flows from operating activities: Net income $ 460 $ 347 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 160 130 Amortization of deferred commissions 145 131 Stock-based compensation 470 422 Deferred income taxes 32 28 Other 4 ( 18 ) Changes in operating assets and liabilities, net of effect of business combinations: Accounts receivable 901 715 Deferred commissions ( 155 ) ( 165 ) Prepaid expenses and other assets ( 139 ) ( 106 ) Accounts payable 234 107 Deferred revenue ( 148 ) ( 10 ) Accrued expenses and other liabilities ( 287 ) ( 240 ) Net cash provided by operating activities $ 1,677 $ 1,341 Cash flows from investing activities: Purchases of property and equipment ( 205 ) ( 135 ) Business combinations, net of cash acquired ( 18 ) ( 10 ) Purchases of other intangibles ( 34 ) ( 21 ) Purchases of investments ( 1,140 ) ( 1,605 ) Purchases of non-marketable investments ( 4 ) ( 42 ) Sales and maturities of investments 1,181 1,073 Other 3 6 Net cash used in investing activities $ ( 217 ) $ ( 734 ) Cash flows from financing activities: Proceeds from employee stock plans 153 131 Repurchases of common stock ( 298 ) ( 175 ) Taxes paid related to net share settlement of equity awards ( 253 ) ( 215 ) Business combination \u2014 ( 184 ) Net cash used in financing activities $ ( 398 ) $ ( 443 ) Foreign currency effect on cash, cash equivalents and restricted cash 5 ( 4 ) Net change in cash, cash equivalents and restricted cash 1,067 160 Cash, cash equivalents and restricted cash at beginning of period 2,310 1,904 Cash, cash equivalents and restricted cash at end of period $ 3,377 $ 2,064 Cash, cash equivalents and restricted cash at end of period: Cash and cash equivalents $ 3,369 $ 2,056 Restricted cash included in prepaid expenses and other current assets 8 8 Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows $ 3,377 $ 2,064 Supplemental disclosures of other cash flow information: Interest paid $ 11 $ 11 Income tax\nlows (in millions): March 31, 2025 Due within 1 year $ 3,228 Due in 1 year through 5 years 4,248 Instruments not due in single maturity 87 Total $ 7,563 As of March 31, 2025 and December\u00a031, 2024, unrealized losses of $ 16 million and $ 18 million, respectively, are from available-for-sale debt securities in a continuous unrealized loss position greater than 12 months. We accrue for loss contingencies when it is both probable that we will incur the loss and when we can reasonably estimate the amount of the loss or range of loss. QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISK There have been no material changes in our market risk compared to the disclosures in Part II, Item 7A in our Annual Report on Form 10-K for the year ended December\u00a031, 2024, which was filed with the SEC on January\u00a030, 2025. Forward-looking snippets: For all available-for-sale debt securities that were in unrealized loss positions, we have determined that it is more likely than not we will hold the securities until maturity or a recovery of the cost basis. RPO excludes contracts that are billed in arrears, such as certain time and materials contracts, as we apply the \u201cright to invoice\u201d practical expedient under relevant accounting guidance. As of March 31, 2025, the total non-cancellable RPO under our contracts with customers was $ 22.1 billion and we expect to recognize revenues on approximately 47 % of these RPO over the following 12 months. RPO excludes contracts that are billed in arrears, such as certain time and materials contracts, as we apply the \u201cright to invoice\u201d practical expedient under relevant accounting guidance. As of March 31, 2025, the total non-cancellable RPO under our contracts with customers was $ 22.1 billion and we expect to recognize revenues on approximately 47 % of these RPO over the following 12 months."
}